Optimi Health, a Canada-based pharmaceuticals maker specializing in MDMA and psilocybin, filed on Friday with the SEC to raise up to $25 million in an initial public offering.
Optimi Health is currently listed on the Canadian Securities Exchange (OPTI), the Frankfurt Stock Exchange (8BN) and the OTCQX (OPTH). It will be excluded from our stats if the market cap is less than $50 million at the time of the uplisting.
The company is a licensed Canadian drug manufacturer that produces controlled substances like MDMA and psilocybin. It operates two facilities in British Columbia and holds multiple licenses that allow it to manufacture, import, and distribute these substances within legal limits. Its approvals cover everything from producing active ingredients from plants to handling and supplying psychedelics in regulated quantities.
The Princeton, Canada-based company was founded in 2020 and booked $568 thousand in revenue for the 12 months ended June 30, 2025. It plans to list on the Nasdaq under the symbol OPTH. Optimi Health filed confidentially on August 8, 2025. Titan Partners is the sole bookrunner on the deal. No pricing terms were disclosed.
